MedTrace Logo

Direct Tumor Injection KLH-Pulsed Dendritic Cells in Unresectable Pancreatic Cancer

NCT00868114 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2018-10-17

No results posted yet for this study

Summary

This research study uses radiation or a gene therapy agent, TNFerade in addition to a dendritic cell vaccine in patients with locally advanced or low volume metastatic pancreatic cancer. The use of TNFerade or radiation serves to generate cell death stimulating the immune response. The dendritic cell vaccine may direct a distant and lasting effective anti-tumor immune response to achieve a local and systemic clinical benefit.

Conditions

Interventions

BIOLOGICAL

KLH-pulsed autologous dendritic cell vaccine

5 X10e7 KLH-pulsed autologous dendritic cell vaccine once weekly times three weeks

Sponsors & Collaborators

  • H. Lee Moffitt Cancer Center and Research Institute

    collaborator OTHER

  • Leo W. Jenkins Cancer Center

    lead OTHER

Principal Investigators

  • Emmanuel E Zervos, MD · East Carolina University - Leo W. Jenkins Cancer Center

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-07-31
Primary Completion
2013-07-31
Completion
2015-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00868114 on ClinicalTrials.gov